Forschungsprojekte
Ergebnisse pro Seite:
100
2018 - 2021
Reach3 - Jakavi bei steroidrefraktärer chronischer GVHD (#743)- Dr. Eva MariaWagner-Drouet
2018 - 2021
Target antigens of tumor-specific TILs in NSCLC- Dr. VolkerLennerz,
- Univ.-Prof. Dr. ThomasWölfel
2018 - 2021
Molecular T cell immunotherapy and inhibition of tumour immune escape mechanisms (Teilprojekt TP06 des SFB 1292)- PD Dr. MarkusMunder,
- Univ.-Prof. Dr. MatthiasTheobald
2018 - 2020
„Song of life“ – Evaluation einer musiktherapiebasierten psychosozialen Intervention zur Verbesserung der Lebensqualität bei unheilbar kranken Patienten- Univ.-Prof. Dr. MartinWeber
2018 - 2021
ERS SHARP (Severe Heterogeneous Asthma Research collaboration, Patient-centered)- PD Dr. StephanieKorn
2018 - 2019
The impact of immunosuppressant Ruxolitinib on neutrophil effector functions (IUFF-Projekt)- Dr. PamelaAranda Lopez
2018 - 2019
Exploring human T lymphocytes redirected to the tumor neoantigen EGFRvIII for adoptive cellular immunotherapy of non small cell lung cancer- Dr. AnitaBhatti,
- Dr. Udo F.Hartwig
2018 - 2020
Bedeutung von Serum in der GVHD-Entstehung- Dr. Eva MariaWagner-Drouet,
- Dr. PascalWölfinger
2018
The role of Triggering Receptor Expressed on Myeloid Cells (TREM)-1 in skin inflammation (SFB TRR 156)- Prof. Dr. MarkusRadsak,
- Univ.-Prof. Dr. AlexanderWeber,
- Dr. PamelaAranda Lopez
2017 - 2019
Multizentrische Studie zur Erprobung der Machbarkeit des mehrmaligen Einsatzes der Demoralisierungsskala bei Patienten mit unheilbarer Erkrankung auf Palliativstationen in Mainz und Wiesbaden (DEMO) (#747)- Univ.-Prof. Dr. MartinWeber,
- SandraMai,
- AnnikaVogt
2017 - 2020
ERANet-LAC CODE. International Care of the Dying Evaluation (CODE): quality of care for cancer patients as perceived by bereaved relatives- Dr. ChristinaGerlach,
- Univ.-Prof. Dr. MartinWeber
2017 - 2020
PosPros - Palliative Outcome Scale in Prostate Cancer- Dr. ChristinaGerlach,
- Univ.-Prof. Dr. MartinWeber
2017 - 2019
Impact of mutational pathways on immune environment, neoantigens and tumor rejection for the development of comprehensive biomarker panels in cancer immunotherapy- Prof. Dr. AngelaKrackhardt,
- Prof. Dr. StefanFröhling,
- Prof. Dr. WilkoWeichert,
- Prof. Dr. HannoGlimm,
- Prof. Dr. BenediktBrors,
- Prof. Dr. PeterSchirmacher,
- Dr. FelixLasitschka,
- Dr. AlbrechtStenziger,
- Prof. Dr. RolandRad,
- Prof. Dr. KarstenSpiekermann,
- Prof. Dr. MarionSubklewe,
- Prof. Dr. ChristianBrandts,
- PD Dr. ThomasKindler,
- Prof. Dr. FlorianGreten,
- Univ.-Prof. Dr. ThomasWölfel,
- Univ.-Prof. Dr. MatthiasTheobald,
- Dr. HakimEchchannaoui,
- Prof. Dr. SebastianBauer,
- JensSiveke,
- Prof. Dr. Nikolasvon Bubnoff,
- Dr. MelanieBörries,
- Prof. Dr. SilkeLassmann,
- Dr. StefanHaug,
- Prof. Dr. MartinWerner,
- PD Dr. GunnarFolprecht,
- Prof. Dr. EvelinSchrock,
- Dr. BarbaraKlink,
- PD Dr. AnneLetsch,
- PD Dr. SebastianOchsenreither,
- PD Dr. FrederickKlauschen,
- Prof. Dr. MatthiasMann,
- Prof. Dr. JürgenCox
2017 - 2018
Preclinical testing of adoptive T-cell receptor gene transfer in combination with checkpoint inhibitors and T-cell agonists as a novel therapy for multiple myeloma- Dr. HakimEchchannaoui,
- PD Dr. MarkusMunder
2017 - 2019
Chimeric antigen receptor-engineered natural killer cells as a universal cellular therapeutic for adoptive cancer immunotherapy (collaborative research project within translational immunotherapy program)- Prof. Dr. WinfriedWels,
- Univ.-Prof. Dr. MatthiasTheobald,
- Prof. Dr. MichaelBachmann,
- Prof. Dr. AchimTemme,
- Prof. Dr. TorstenTonn,
- Prof. Dr. DirkJäger,
- PD Dr. JessicaHassel,
- Prof. Dr. JürgenBecker,
- PD Dr. AnnettePaschen
2017 - 2018
L-arginine depletion in combination with L-canavanine supplementation: a novel treatment strategy for multiple myeloma- Dr. JohannesWindschmitt
2017 - 2040
Untersuchung zum HLA-DP-Mismatch bei allogener Stammzelltransplantation (#725)- Dr. Eva MariaWagner-Drouet
2017 - 2020
Geschmacks- und Geruchsveränderungen nach allogener Stammzelltransplantation- Dr. Eva MariaWagner-Drouet
2017 - 2024
Epigenetische Kontrolle leukämogener Genexpression durch Menin und MLL1-Komplexpartner-Proteine- Dr. MichaelKühn
2017 - 2022
Junior Group of the German Cancer Consortium (DKTK)- Dr. BorhaneGuezguez,
- Univ.-Prof. Dr. MatthiasTheobald
2017 - 2020
Genomic editing of human T cells for improved adoptive cellular immunotherapy using CRISPR/Cas9 technology- PD Dr. Udo F.Hartwig,
- SedighehGivi
2017 - 2019
AG-221 bei fortgeschrittener AML mit IDH2 Mutation in älteren Patienten (#623)- Prof. Dr. MarkusRadsak
2017 - 2018
Frühintegration interdisziplinärer und multiprofessioneller palliativmedizinischer Interventionen bei ambulanten Patienten durch Palliativmedizinische Tagestherapie- Dr. ChristinaGerlach,
- Univ.-Prof. Dr. MartinWeber
2017
PI3Kδ isoform in TREM-1 mediated neutrophil inflammatory responses (IUFF Stufe 1)- Dr. AstridHasibeder
2017 - 2021
Proteine auf Nanocarriern: vom Stealth Effekt zu einem gezielten Targeting in vivo- Univ.-Prof. Dr. StefanTenzer,
- Prof. Dr. TanjaWeil,
- Prof. Dr. VolkerMailänder
2017 - 2018
Chromatin-based mechanisms of oncogenic therapy-related MLL translocations- PD Dr. ThomasKindler
2017 - 2018
Tailoring Transcutaneous Immunization for optimal T–helper cell activation- Prof. Dr. MarkusRadsak
2017 - 2019
AFM11 in patients with relapsed and/or refractory CD19 positive B-cell NHL (#667)- Univ.-Prof. Dr. GeorgHeß
2017 - 2019
Targets for cancer therapy by integration of gene expression and toxicity data. (NMFZ)- Univ.-Prof. Dr. MiguelAndrade,
- Univ.-Prof. Dr. LeszekWojnowski,
- Univ.-Prof. Dr. ThomasKindler
2017 - 2020
Engineering Tumor Antigen-specific T cells from pluripotent stem cells as novel source for cancer immunotherapy applications- Dr. BorhaneGuezguez
2017 - 2020
Phase I trial of MSC2490484A in combination with radiotherapy (#677)- Univ.-Prof. Dr. GeorgHeß
2017 - 2019
CA209-602 : Pomalidomid +/- Nivolumab +/- Elotuzumab beim rezidivierten Multiplen Myelom (#682)- PD Dr. MarkusMunder